Latest news with #NKF
Borneo Post
25-05-2025
- Business
- Borneo Post
Seek legal advice over tax exemption cancellations, SUPP Dudong man tells charitable bodies
Wong greets members of the public at a coffeeshop during the SUPP Dudong and Sibujaya's Kopitiam Talk. – Photo by Peter Boon SIBU (May 25): Sarawak United People's Party (SUPP) Dudong branch chairman Wong Ching Yong has urged charitable bodies at risk of getting their tax exemption status cancelled to consult tax accountants and lawyers specialising in taxation. In giving this advice, he revealed that several charitable bodies in Sarawak have had their tax exemption status cancelled by the Inland Revenue Board (IRB), and expressed concern that many did not appeal the decision in court. Citing a recent case, he highlighted how the National Kidney Foundation (NKF) successfully challenged IRB's decision to withdraw its tax exemption status under Section 44(6) of the Income Tax Act 1967 (ITA) through a judicial review in the High Court. 'In Sarawak, I have been made aware of several charitable bodies whose tax exemption status was cancelled by IRB. It's regrettable that these organisations did not appeal to the High Court. 'Based on the favourable outcome in the NKF case, I strongly encourage other charitable bodies facing similar challenges to seek legal advice. Do not give up or surrender your right to a judicial review,' he said this when met after the SUPP Dudong and Sibujaya's Kopitiam Talk at a coffeeshop here yesterday. Wong pointed out that charities in Malaysia are operated by people who are professional, honest individuals of high standing in the society. 'I personally have had good experience with the Board of Trustees of the Kidney Foundation in Sibu. However, I was informed that the foundation's tax exemption status was cancelled some years ago. 'This is detrimental to any charities, as tax exemptions are very attractive for donors, who enjoy tax benefits on their donations to charity. 'The IRB policy of even cancelling the tax exemption status of charitable bodies indicates that the government's coffers are very low. Once again, it is high time to bring back the Goods and Services Tax (GST) to broaden Malaysia's tax base,' he said. During the programme, SUPP Dudong and Sibujaya's mobile service teams reached out to individuals having any livelihood issues or community concerns. Also present was SUPP Sibujaya chairman Kong Sing Ping. charitable bodies Court legal SUPP Dudong tax exemption Wong Ching Yong
Yahoo
14-05-2025
- Business
- Yahoo
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
- Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025 - New data from patient surveys and patient-reported outcomes studies highlight adherence challenges for patients with hyperphosphatemia on dialysis and emphasize the market potential of OLC LOS ALTOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended March 31, 2025, and provided a business update. 'We are making incredible strides as we prepare for the potential FDA approval of oxylanthanum carbonate (OLC) so we can bring this treatment to people with chronic kidney disease (CKD) on dialysis as efficiently as possible,' said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. 'The need for our differentiated treatment, which offers high potency and a significantly reduced pill burden for people struggling to control hyperphosphatemia, has been further validated by new patient survey findings and patient-reported outcomes data. We remain dedicated to bolstering our commercial infrastructure as we strive to deliver a much-needed solution to patients and healthcare providers.' Key Highlights & Upcoming Milestones The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025, for OLC. Unicycive continues to prepare for the potential launch of OLC by building key functions, engaging directly with prescribers and other stakeholders, and supporting market access. Expanded awareness of OLC and its potential to address significant needs for CKD patients by publishing data and presentations at medical meetings. Recently, findings were presented at the National Kidney Foundation (NKF) Spring Clinical Meetings and the 2025 American Nephrology Nurses Association (ANNA) National Symposium from a patient survey conducted in partnership with the NKF. The survey included a total of 200 dialysis patients who identified excessive pill numbers, large pill sizes, and forgetfulness as the primary barriers to phosphate binder adherence. Patients also expressed a strong preference for medication regimens with fewer and smaller pills. New patient-reported outcomes data from the pivotal Phase 2 study of OLC were presented at the 2025 American Dialysis Conference (ADC) and the NKF Spring Clinical Meeting, which demonstrated that patients preferred OLC in comparison to their pre-trial phosphate binder medications and significantly enhanced patient satisfaction. Financial Results for the Quarter Ended March 31, 2025 Research and Development (R&D) expenses were $2.2 million for the three months ended March 31, 2025, compared to $6.8 million for the three months ended March 31, 2024. The decrease in research and development expenses was primarily due to decreased drug development costs. General and Administrative (G&A) expenses were $5.8 million for the three months ended March 31, 2025, compared to $2.4 million for the three months ended March 31, 2024. The increase was primarily due to increased consulting and professional services related to our commercial launch preparation. In addition to the above launch expenses, we continue to focus on the manufacturing of commercial supplies, as reflected in prepaid expenses and other current assets on our balance sheet which increased from $4.8 million as of December 31, 2024 to $7.6 million as of March 31, 2025. Other income was $8.6 million for the three months ended March 31, 2025, compared to an expense of $11.8 million for the three months ended March 31, 2024, primarily due to a decrease in the fair value of our warrant liability. Net income attributable to common stockholders for the three months ended March 31, 2025, was $0.5 million, compared to a net loss attributable to common stockholders of $21.2 million for the three months ended March 31, 2024. The net income for the three-month period ended March 31, 2025, was primarily due to a decrease in the fair value of our warrant liability. As of March 31, 2025, cash and cash equivalents totaled $19.8 million. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive's second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information about Unicycive, visit and follow us on LinkedIn and X. Forward-looking statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; our need to raise substantial additional capital in the future to fund our continuing operations and the development and commercialization of our current product candidates and future product candidates; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; risks related to delays in obtaining or failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; and our failure, or the failure of our third-party manufacturers, or their subcontractors, to comply with cGMPs or other applicable regulations, which could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Unicycive's Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Investor Contacts: Kevin GardnerLifeSci Advisorskgardner@ Media Contact: Rachel Visi Real Chemistryredery@ SOURCE: Unicycive Therapeutics, Therapeutics, Inc. Balance Sheets (in thousands, except for share and per share amounts) As of As of December 31, March 31, 2024 2025 (Unaudited) Assets Current assets: Cash $ 26,142 $ 19,769 Prepaid expenses and other current assets 4,806 7,577 Total current assets 30,948 27,346 Right of use asset, net 645 518 Property, plant and equipment, net 75 83 Total assets $ 31,668 $ 27,947 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,058 $ 1,397 Accrued liabilities 3,562 4,143 Warrant liability 18,936 10,588 Operating lease liability - current 564 548 Total current liabilities 24,120 16,676 Operating lease liability - long term 117 - Total liabilities 24,237 16,676 Commitments and contingencies Stockholders' equity: Series A-2 Prime preferred stock, $0.001 par value per share - 21,338.01 Series A-2 Prime shares authorized at December 31, 2024 and March 31, 2025; 6,150.21 and 5,464.21 Series A-2 Prime shares issued and outstanding at December 31, 2024 and March 31, 2025, respectively - - Series B-2 preferred stock, $0.001 par value per share - 7,882 Series B-2 shares authorized at December 31, 2024 and March 31, 2025; 3,000 Series B-2 shares issued and outstanding at December 31, 2024 and March 31, 2025 - - Preferred stock: $0.001 par value per share - 9,846,891 shares authorized at December 31, 2024 and March 31, 2025; zero shares issued and outstanding at December 31, 2024 and March 31, 2025 - - Common stock, $0.001 par value per share - 400,000,000 shares authorized at December 31, 2024 and March 31, 2025; 113,842,364 and 119,749,743 shares issued and outstanding at December 31, 2024 and March 31, 2025, respectively 114 120 Additional paid-in capital 108,587 111,851 Accumulated deficit (101,270 ) (100,700 ) Total stockholders' equity 7,431 11,271 Total liabilities and stockholders' equity $ 31,668 $ 27,947 Unicycive Therapeutics, Inc. Statements of Operations (in thousands, except for share and per share amounts) (Unaudited) Three Months Ended March 31, 2024 2025 Operating expenses: Research and development $ 6,813 $ 2,171 General and administrative 2,391 5,818 Total operating expenses 9,204 7,989 Loss from operations (9,204 ) (7,989 ) Other income (expenses): Interest income 69 226 Interest expense (20 ) (15 ) Change in fair value of warrant liability (11,808 ) 8,348 Total other income (expenses) (11,759 ) 8,559 Net (loss) income (20,963 ) 570 Net (loss) income attributable to common stockholders, basic (21,171 ) 510 Net loss attributable to common stockholders, diluted (21,171 ) (6,214 ) Net (loss) income per share: Basic $ (0.61 ) $ - Diluted $ (0.61 ) $ (0.05 ) Weighted-average shares outstanding: Basic 34,912,692 116,818,811 Diluted 34,912,692 123,834,773
Borneo Post
11-05-2025
- Health
- Borneo Post
Sarawak sees 700-800 new kidney failure cases annually, 4,800 now on dialysis, says SGH nephrologist
Dr Tan fields questions from reporters at the event. – Photo by Jude Toyat KUCHING (May 11): Sarawak records between 700 and 800 new cases of kidney failure annually, with approximately 4,800 patients currently undergoing dialysis. This alarming figure was revealed by Sarawak General Hospital (HUS) consultant nephrologist Dr Clare Tan Hui Hong during the launch of World Kidney Day 2025 at a shopping mall here today. 'Every year, we have about 700 to 800 new patients diagnosed with kidney failure who need to start dialysis. In total, we currently have around 4,800 patients on dialysis in Sarawak,' she told reporters after officiating the launch. Dr Tan said the increasing number of kidney failure cases is concerning, emphasising the urgent need for preventive measures and greater public awareness. 'Dialysis centres are expanding. There are about 25 government-run dialysis facilities across Sarawak, with a new one set to open in Selangau Health Clinic by the end of the year. We also have around 12 charity-run centres, and more are in the pipeline,' she said. Despite the growing number of dialysis centres, Dr Tan stressed that prevention remains far more critical than treatment. 'More than just focusing on dialysis, we must address the root issue — prevention. Raising awareness about kidney health is essential to slowing down the number of people progressing to kidney failure.' She also cited national health survey data showing a worrying trend: the prevalence of chronic kidney disease (CKD) in Malaysia increased from 9.07 per cent in 2011 to 15.5 per cent in 2018 — rising from roughly one in 11 persons to one in six or seven. Although no new nationwide surveys have been conducted since 2018, Dr Tan expressed hope that initiatives like World Kidney Day campaigns could reverse the upward trend. This year's World Kidney Day carries the theme 'Detect Early, Protect Kidney Health', emphasising the importance of early detection and lifestyle interventions in reducing CKD cases. 'Let us work together to fight the epidemic of chronic kidney disease and to stop this epidemic,' Dr Tan urged. Also present at the event were Kelab Rotary Kuching president Charlie Ong, COR Holder of NKF Kota Samarahan Dr Nurizaidah Ishak, and NKF Kota Samarahan regional unit coordinator Nur Ezzatul Sahadah Jelani. dialysis Dr Clare Tan kidney failure lead
Arabian Post
07-05-2025
- Business
- Arabian Post
Bee Choo Origin Strengthens CSR Efforts with Electric Van Donation to NKF
Bee Choo Origin Strengthens CSR Efforts with Electric Van Donation to NKF This donation is part of the long tradition of Bee Choo Origin supporting NKF, reflecting its dedication to making a positive impact beyond the beauty industry. The electric van, which is the first of its kind in NKF's fleet, will be used to provide transportation for kidney patients who require regular dialysis treatments but face difficulties commuting to and from medical centres. Providing Safe and Eco-Friendly Transport for Kidney Patients The donation from Bee Choo Origin supports NKF's Wheeling for Love & Hope Programme, which provides free transport services to patients struggling with mobility issues. The new electric van is designed with built-in access steps and spacious seating, ensuring safe and comfortable travel for patients. It is expected to facilitate up to 1,044 trips annually, benefiting approximately 72 patients per week. For many kidney patients, travelling to dialysis centres three times a week can be physically demanding and financially burdensome. NKF's transport programme alleviates this challenge, offering patients reliable and accessible transportation at no cost. The introduction of an electric van further enhances this initiative by reducing carbon emissions and lowering operational costs in the long run. 'We're deeply honoured to partner with NKF on this meaningful initiative,' said Ms. Lim Xue Ting, General Manager of Bee Choo Origin. 'Dialysis is a lifeline for many, and we hope this contribution helps ease the journey for patients while also supporting a greener, more sustainable future. At Bee Choo Origin, community care and environmental responsibility are values we hold close, and this donation is a reflection of our ongoing commitment to both.' Bee Choo Origin: A Legacy of Giving Back Bee Choo Origin has been a steadfast supporter of NKF for several years, previously donating five dialysis machines since 2018 to enhance treatment capacity. The latest contribution of an electric van builds upon this partnership, reinforcing the brand's dedication to social good. Beyond its work with NKF, Bee Choo Origin has actively supported various charitable organisations through its CSR initiatives, including: Cerebral Palsy Alliance Singapore (CPAS) – Through their partnership with the Goodwill, Rehabilitation & Occupational Workshop (GROW), Bee Choo Origin contributes to empowering individuals with cerebral palsy by supporting initiatives that promote meaningful employment, skills development, and greater independence. – Through their partnership with the Goodwill, Rehabilitation & Occupational Workshop (GROW), Bee Choo Origin contributes to empowering individuals with cerebral palsy by supporting initiatives that promote meaningful employment, skills development, and greater independence. Metta Welfare Association – Bee Choo Origin supports Metta's programmes and the Maitri School, which focuses on uplifting individuals with special needs through tailored education, dedicated care, and inclusive community engagement. – Bee Choo Origin supports Metta's programmes and the Maitri School, which focuses on uplifting individuals with special needs through tailored education, dedicated care, and inclusive community engagement. A Packet of Rice – By sponsoring meals, Bee Choo Origin helps provide essential nourishment to underprivileged individuals and families across Singapore, contributing to food security and community welfare. In 2019, the brand's founder, Mdm Cheah Bee Chew, personally donated $150,000 from the sales proceeds of her biography to multiple social causes, demonstrating her deep-rooted belief in philanthropy. A Commitment to Sustainability and Future CSR Initiatives As Bee Choo Origin celebrates its 25th anniversary, the brand is looking ahead to more initiatives that align with both environmental responsibility and community welfare. The transition to electric transport solutions is a step towards reducing carbon footprints while improving the quality of life for those in need. 'We believe that businesses have a responsibility to contribute to society in meaningful ways,' added Ms. Lim Xue Ting. 'Every act of kindness, no matter how small, can make a difference. We hope our contributions inspire other companies and individuals to support those in need.' Moving forward, the brand's CSR efforts will continue to focus on improving lives and giving back to the community. Plans are already underway for future community initiatives, reinforcing the brand's mission of creating lasting positive #BeeChooOrigin The issuer is solely responsible for the content of this announcement. About Bee Choo Origin Founded in 2000, Bee Choo Origin is Singapore's leading hair care brand, specialising in natural, chemical-free herbal hair treatment for hair loss and scalp health. With a commitment to quality and innovation, Bee Choo Origin has expanded globally, offering effective treatments backed by traditional Chinese herbs and modern science. Beyond hair care, the brand actively supports community initiatives, including healthcare and sustainability efforts, reinforcing its dedication to making a positive impact in both beauty and society.
Zawya
07-05-2025
- Business
- Zawya
Bee Choo Origin Strengthens CSR Efforts with Electric Van Donation to NKF
SINGAPORE - Media OutReach Newswire - 7 May 2025 – Bee Choo Origin, Singapore's leading herbal hair care brand that specialises in hair fall treatment and oily scalp treatment, has reaffirmed its commitment to corporate social responsibility (CSR) with the donation of an electric passenger van to The National Kidney Foundation (NKF). This marks a significant step in enhancing patient mobility while promoting sustainable transport solutions. This donation is part of the long tradition of Bee Choo Origin supporting NKF, reflecting its dedication to making a positive impact beyond the beauty industry. The electric van, which is the first of its kind in NKF's fleet, will be used to provide transportation for kidney patients who require regular dialysis treatments but face difficulties commuting to and from medical centres. Providing Safe and Eco-Friendly Transport for Kidney Patients The donation from Bee Choo Origin supports NKF's Wheeling for Love & Hope Programme, which provides free transport services to patients struggling with mobility issues. The new electric van is designed with built-in access steps and spacious seating, ensuring safe and comfortable travel for patients. It is expected to facilitate up to 1,044 trips annually, benefiting approximately 72 patients per week. For many kidney patients, travelling to dialysis centres three times a week can be physically demanding and financially burdensome. NKF's transport programme alleviates this challenge, offering patients reliable and accessible transportation at no cost. The introduction of an electric van further enhances this initiative by reducing carbon emissions and lowering operational costs in the long run. 'We're deeply honoured to partner with NKF on this meaningful initiative,' said Ms. Lim Xue Ting, General Manager of Bee Choo Origin. 'Dialysis is a lifeline for many, and we hope this contribution helps ease the journey for patients while also supporting a greener, more sustainable future. At Bee Choo Origin, community care and environmental responsibility are values we hold close, and this donation is a reflection of our ongoing commitment to both.' Bee Choo Origin: A Legacy of Giving Back Bee Choo Origin has been a steadfast supporter of NKF for several years, previously donating five dialysis machines since 2018 to enhance treatment capacity. The latest contribution of an electric van builds upon this partnership, reinforcing the brand's dedication to social good. Beyond its work with NKF, Bee Choo Origin has actively supported various charitable organisations through its CSR initiatives, including: Cerebral Palsy Alliance Singapore (CPAS) – Through their partnership with the Goodwill, Rehabilitation & Occupational Workshop (GROW), Bee Choo Origin contributes to empowering individuals with cerebral palsy by supporting initiatives that promote meaningful employment, skills development, and greater independence. Metta Welfare Association – Bee Choo Origin supports Metta's programmes and the Maitri School, which focuses on uplifting individuals with special needs through tailored education, dedicated care, and inclusive community engagement. A Packet of Rice – By sponsoring meals, Bee Choo Origin helps provide essential nourishment to underprivileged individuals and families across Singapore, contributing to food security and community welfare. In 2019, the brand's founder, Mdm Cheah Bee Chew, personally donated $150,000 from the sales proceeds of her biography to multiple social causes, demonstrating her deep-rooted belief in philanthropy. A Commitment to Sustainability and Future CSR Initiatives As Bee Choo Origin celebrates its 25th anniversary, the brand is looking ahead to more initiatives that align with both environmental responsibility and community welfare. The transition to electric transport solutions is a step towards reducing carbon footprints while improving the quality of life for those in need. "We believe that businesses have a responsibility to contribute to society in meaningful ways," added Ms. Lim Xue Ting. "Every act of kindness, no matter how small, can make a difference. We hope our contributions inspire other companies and individuals to support those in need." Moving forward, the brand's CSR efforts will continue to focus on improving lives and giving back to the community. Plans are already underway for future community initiatives, reinforcing the brand's mission of creating lasting positive #BeeChooOrigin The issuer is solely responsible for the content of this announcement. About Bee Choo Origin Founded in 2000, Bee Choo Origin is Singapore's leading hair care brand, specialising in natural, chemical-free herbal hair treatment for hair loss and scalp health. With a commitment to quality and innovation, Bee Choo Origin has expanded globally, offering effective treatments backed by traditional Chinese herbs and modern science. Beyond hair care, the brand actively supports community initiatives, including healthcare and sustainability efforts, reinforcing its dedication to making a positive impact in both beauty and society. Bee Choo Origin
